Vol 27, No 6 (2020)
Original Article
Published online: 2018-06-14

open access

Page views 3664
Article views/downloads 1722
Get Citation

Connect on Social Media

Connect on Social Media

The atherogenic index of plasma and its impact on recanalization of chronic total occlusion

Jan-Erik Guelker1, Alexander Bufe1, Christian Blockhaus1, Knut Kroeger1, Thomas Rock1, Ibrahim Akin2, Michael Behnes2, Kambis Mashayekhi3
Pubmed: 29924378
Cardiol J 2020;27(6):756-761.


Background: The plasma-derived atherogenic index (AIP) is associated with an increasing risk for cardiovascular diseases. Whether an increased AIP may predict the complexity of percutaneous coronary intervention (PCI) of chronic total occlusion (CTO), according to available research, has never been investigated before.

Methods: Three hundred seventeen patients were included prospectively and treated with PCI for at least one CTO between 2012 and 2017. High-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) plasma levels were measured 24 h before PCI. All patients were stratified into tertiles of AIP (defined as 0.11, 0.11–0.21, > 0.21) based on their TG/HDL-C (AIP) levels.

Results: Mean AIP of all patients undergoing CTO-PCI was 0.53 ± 0.29. The majority of patients were male (82.6%), and mean age was 61 ± 10.4 years. Increased AIP > 0.21 was associated with longer occlusion length (statistical trend p = 0.082) and stent routes (p = 0.022) and with a higher number of implanted stents (n > 4) (statistical trend p = 0.072). Success rates were similar in all AIP categories (p = 0.461). In-hospital PCI-related complications were rare and not statistically different (p = 0.852).

Conclusions: This study demonstrates for the first time that an increased AIP may predict the complexity of CTO-PCI and additionally may help to improve planning and quality of CTO-PCI.

Article available in PDF format

View PDF Download PDF file


  1. Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012; 59(11): 991–997.
  2. Tomasello SD, Boukhris M, Giubilato S, et al. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015; 36(45): 3189–3198.
  3. Bufe A, Haltern G, Dinh W, et al. Recanalisation of coronary chronic total occlusions with new techniques including the retrograde approach via collaterals. Neth Heart J. 2011; 19(4): 162–167.
  4. Galassi AR, Tomasello SD, Reifart N, et al. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. EuroIntervention. 2011; 7(4): 472–479.
  5. Stähli BE, Gebhard C, Gick M, et al. Impact of body mass index on long-term mortality in women and men undergoing percutaneous coronary intervention for chronic total occlusion. Int J Cardiol. 2016; 224: 305–309.
  6. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001; 161(22): 2685–2692.
  7. Lemos da Luz P, Favarato D, Faria-Neto Junior JR, et al. High ratio of triglycerides to hdl-cholesterol predicts extensive coronary disease. Clinics. 2008; 63(4).
  8. Khazaál MS. Atherogenic Index of Plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios). Karbala J Med. 2013; 6(1): 1506–11.
  9. Morino Y, Abe M, Morimoto T, et al. J-CTO Registry Investigators. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv. 2011; 4(2): 213–221.
  10. Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd.
  11. Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001; 34(7): 583–588.
  12. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran. 2015; 29: 240.
  13. Wan Ke, Zhao J, Huang H, et al. The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization. PLoS One. 2015; 10(4): e0123521.
  14. Lee MiJ, Park JT, Han SH, et al. The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea. PLoS One. 2017; 12(5): e0177499.
  15. Shimizu Y, Nakazato M, Sekita T, et al. Association of arterial stiffness and diabetes with triglycerides-to-HDL cholesterol ratio for Japanese men: the Nagasaki Islands Study. Atherosclerosis. 2013; 228(2): 491–495.
  16. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005; 96(3): 399–404.
  17. Hermans MP, Ahn SA, Rousseau MF. log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol. 2010; 9: 88.
  18. Onat A, Can G, Kaya H, et al. "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010; 4(2): 89–98.
  19. Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012; 11: 132.
  20. Kanthe PS, Patil BS, Bagali Sh, et al. Atherogenic Index as a Predictor of Cardiovascular Risk among Women with Different Grades of Obesity. IJCRIMPH. 2012; 4(10): 1767–1774.
  21. Flier JS. Biology of Obesity. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. eds. Harrison’s Principles of Internal Medicine.17th ed. New York, NY : 462–464.
  22. Yildiz G, Duman A, Aydin H, et al. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial Int. 2013; 17(3): 397–405.
  23. Ni W, Zhou Z, Liu T, et al. Gender-and lesion number-dependent difference in "atherogenic index of plasma" in Chinese people with coronary heart disease. Sci Rep. 2017; 7(1): 13207.
  24. Gritzenko O, Chumakova G, Veselovskaya N. Atherogenic indexes as predictors of stenotic complication after percutaneous coronary interventions or coronary artery bypass graft. Atherosclerosis. 2015; 241(1): e212.